Evaluation of a fixed combination of timolol maleate, hydrochlorothiazide and amiloride hydrochloride in the treatment of hypertension: A long-term multicentre trial.
The effect of a single daily dose of timolol, hydrochlorothiazide and amiloride hydrochloride in fixed combination (Moducren; MDS) in patients with mild to moderate essential hypertension was tested during 1978 in an open study covering 10 weeks per patient. This was subsequently extended to cover a total of 50 weeks per patient, and the results are compared. Of the patients studied during phase 1, 91,5% responded with a fall in diastolic blood pressure of 10 mmHg or more. This figure decreased to 87,5% during phase 2, but none the less remained satisfactory. A single daily dose of one tablet or less of the trial preparation proved effective in the majority of patients (75%). Adverse effects were infrequent and usually of a minor nature.
D000328:Adult; D000368:Aged; D000584:Amiloride / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D003971:Diastole / Q000187:drug effects; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011188:Potassium / Q000097:blood; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D011719:Pyrazines / Q000627:therapeutic use*; D013599:Systole / Q000187:drug effects; D013997:Time Factors; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
D004338:Drug Combinations; D011412:Propanolamines; D011719:Pyrazines; D006852:Hydrochlorothiazide; D014527:Uric Acid; D000584:Amiloride; D013999:Timolol; D011188:Potassium